Development and Validation of Tumor Immunogenicity Based Gene Signature for Skin Cancer Risk Stratification.

ABSTRACT: Melanoma is one of the most aggressive types of skin cancer, with significant heterogeneity in overall survival. Currently, tumor-node-metastasis (TNM) staging is insufficient to provide accurate survival prediction and appropriate treatment decision making for several types of tumors, such as those in melanoma patients. Therefore, the identification of more reliable prognosis biomarkers is urgently essential. Recent studies have shown that low immune cells infiltration is significantly associated with unfavorable clinical outcome in melanoma patients. Here we constructed a prognostic-related gene signature for melanoma risk stratification by quantifying the levels of several cancer hallmarks and identify the Wnt/β-catenin activation pathway as a primary risk factor for low tumor immunity.

SUBMITTER: Yavartanoo M 

PROVIDER: S-EPMC8584987 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature